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Introduction {#sec1}
============

Most studies on the mechanisms that regulate human pluripotency have focused on protein-coding genes, which constitute less than 5% of the human genome. In contrast, TEs, which account for nearly half the human genome, have received significantly less attention. Recent reports have shown that TEs are dynamically expressed in human germline cells, the naive and primed states of human pluripotency, human pre-implantation embryos, and human germ cell tumors ([@bib8], [@bib9], [@bib10], [@bib16], [@bib31], [@bib34]). Yet the mechanisms that regulate the dynamic expression of TEs in human pluripotency and human germline development are not well understood.

One of the most dynamically expressed families of TEs in human pre-implantation embryos are long terminal repeat (LTR) retrotransposons, which constitute about 8% of the human genome ([@bib4]). Notably, full-length human-specific LTR5 (LTR5_HS) human endogenous retroviral K (HERVK) TEs are expressed exclusively in 8-cell, morula, and pre-implantation human epiblast cells as well as in germ cell tumors ([@bib9], [@bib10]). In contrast, the primate-specific LTR7-HERVHs are expressed throughout human pre-implantation embryo development as well as in primed human embryonic stem cells (hESCs), but are repressed when primed hESCs are converted to the naive state ([@bib31]). LTR5_HS TEs regulate viral infection in human pluripotent stem cells, whereas LTR7-HERVHs regulate primed pluripotent stem cell self-renewal ([@bib8], [@bib9], [@bib16], [@bib34]).

Dynamic TE expression is not restricted to human embryos. In the mouse embryo, murine endogenous retrovirus L (MuERV-L) is expressed at the 2-cell and 8-cell stage of mouse embryo development, whereas intracisternal A particles (IAPs) are expressed in mouse oocytes, cleavage embryos, and blastocysts ([@bib28]). Long interspersed nuclear element 1 (LINE1), a non-LTR TE, is expressed during mouse zygotic genome activation where it functions to enable chromatin accessibility ([@bib7], [@bib13], [@bib23]). Therefore TE expression in germline competent pluripotent cells in both mouse and human is a fundamental requirement for pluripotent cell biology.

Although regulation of TE expression in human embryos and pluripotent stem cells is not well known, one of the major mechanisms responsible for regulating TE expression in mouse embryos is *Trim28* (also named Kap1 and Tif1b) ([@bib26], [@bib27], [@bib35], [@bib37]). In mouse, a zygotic knockout of *Trim28* causes embryonic lethality shortly after implantation ([@bib2]), whereas a maternal mouse knockout causes variable epigenetic instability at imprinting control regions (ICRs), and no live births ([@bib18]). In naive mouse ESCs, *Trim28* is essential for repression of IAPs, as well as mouse ESC self-renewal and survival ([@bib23]), whereas in primed hESCs, a short-term knockdown of *TRIM28* leads to HERV derepression ([@bib32]); however, the role of TRIM28 in the basic properties of human primed or naive pluripotency is not known.

In the current study we report the generation of *TRIM28* null mutations in primed and naive hESCs using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein nuclease (Cas9) technology ([@bib3]). We show that a null mutation in *TRIM28* is compatible with both primed and naive human self-renewal, despite massive derepression of TEs. We demonstrate that a null mutation in *TRIM28* leads to loss of human germline competency from primed hESCs, indicating that it is the ability to differentiate into the germline, not pluripotent self-renewal per se, that is particularly sensitive to loss of TRIM28 in humans.

Results {#sec2}
=======

TRIM28 Is Not Required for Primed hESC Self-Renewal {#sec2.1}
---------------------------------------------------

To evaluate the function of TRIM28 in primed hESCs, we generated targeted deletions of *TRIM28* in the genome using CRISPR/Cas9 in the karyotypically normal 46XX UCLA1 and 46XY UCLA6 hESC lines ([@bib6]). To achieve this, we designed paired guide RNAs (gRNAs) that targeted exon 4 and exon 11 of human *TRIM28* ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Following co-electroporation of plasmids expressing the gRNAs and Cas9, individual clones were picked and genotyped. A total of 112 UCLA1 and 48 UCLA6 clones were screened, and we identified two potential homozygous mutant hESC clones in UCLA1 that we called TRIM28 knockout (T28KO) UCLA1-9 (U1-9) and UCLA1-11 (U1-11) and one homozygous mutant in UCLA6 called T28KO U6. Control (Ctrl) clones in UCLA1 and UCLA6 hESC lines were created by electroporating Cas9 without gRNAs. To identify the precise mutation, we performed PCR followed by cloning and Sanger sequencing of individual alleles from the T28KO genome ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Western blot analysis was used to confirm that the TRIM28 protein was not expressed in any of the three sublines of T28KO hESCs relative to Ctrls ([Figure 1](#fig1){ref-type="fig"}A). Therefore, we conclude that our gene-editing approach creates null *TRIM28* mutations in primed hESCs.Figure 1TRIM28 Is Not Required for Primed hESC Self-Renewal or Pluripotency(A) Western blot to detect TRIM28 in control UCLA1 (Ctrl UCLA1), TRIM28KO \#9 and \#11 in UCLA1 (T28KO(U1-9) and T28KO(U1-11)), control UCLA6 (Ctrl UCLA6), and TRIM28KO in UCLA6 (T28KO(U6)) primed hESCs. The top band represents the expected full-length TRIM28 protein (110 kDa). ACTIN is an internal loading control.(B) Average cell counts over 7 days of control (Ctrl UCLA1) and T28KO (T28KO(U1-9)) primed hESC culture (n = 3 independent experiments), ^∗^p \< 0.05. Error bars represent SD.(C) Representative immunofluorescence for OCT4 (red), TRIM28 (green), and nuclei (DAPI). Scale bar, 10 μm.(D) Representative images of H&E-stained teratoma sections from control (Ctrl UCLA1) and T28KO (T28KO(U1-9)) hESCs (n = 6 teratomas). Scale bar, 50 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Unlike in mouse where a null mutation in *Trim28* leads to defects in mouse ESC self-renewal, T28KO hESC lines were capable of self-renewal, maintaining a morphology of round, tightly packed colonies that were indistinguishable from Ctrl ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Analysis of cell number after passaging T28KO and Ctrl UCLA1 sublines revealed that on average T28KO hESC cultures had more cells on day 7 after plating compared with the Ctrl ([Figure 1](#fig1){ref-type="fig"}B), suggesting that T28KO hESCs grow faster. We also discovered that T28KO hESCs are karyotypically normal, even after more than ten passages of culture ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Furthermore, T28KO hESCs expressed typical markers of self-renewal and pluripotency including OCT4 ([Figure 1](#fig1){ref-type="fig"}C), and were capable of teratoma formation when transplanted into immunocompromised mice ([Figure 1](#fig1){ref-type="fig"}D). Although the teratomas contained cell types from the three somatic lineages based on histology, the T28KO teratomas were darkly pigmented upon necropsy, and histological analysis indicated an abundance of highly pigmented somatic cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These pigmented cells were rarely identified in teratomas derived from Ctrl hESCs. Therefore, our data indicate that a null mutation in TRIM28 has no effect on self-renewal or pluripotency in primed conditions; instead, it is associated with faster growth and a preference for generating pigmented somatic cells in teratoma assays together with cell types representing the major somatic embryonic layers.

TRIM28 Is Required for Germline Competency {#sec2.2}
------------------------------------------

Although the teratoma assay is a non-quantitative method for assessing the ability to differentiate into somatic cells, it provides no clues as to whether hESC lines are germline competent. To address this, we differentiated Ctrl and T28KO hESCs into human primordial germ cell-like cells (hPGCLCs) following the protocol established by [@bib25]. In this approach, hPGCLCs are differentiated through a two-step protocol involving 24 hr of adherent differentiation to create incipient mesoderm-like cells (iMeLCs), followed by aggregate differentiation in 96-well plates to create aggregates containing hPGCLCs ([Figure 2](#fig2){ref-type="fig"}A). To identify hPGCLCs in the aggregates, we used fluorescence-activated cell sorting (FACS) to isolate hPGCLCs expressing the cell surface receptors integrin alpha 6 (ITGA6) and epithelial cell adhesion molecule (EPCAM) ([Figure 2](#fig2){ref-type="fig"}B). Our results showed that Ctrl UCLA1 and UCLA6 hESCs had a clearly defined ITGA6/EPCAM double-positive hPGCLC population at day 4 of differentiation ([Figure 2](#fig2){ref-type="fig"}B), whereas all three T28KO sublines did not produce hPGCLCs ([Figure 2](#fig2){ref-type="fig"}B); we quantified the percentages of the double-positive populations ([Figure 2](#fig2){ref-type="fig"}C). Therefore, *TRIM28* null hESCs cultured in the primed state of pluripotency have lost germline competency.Figure 2TRIM28KO hESCs Are Germline Incompetent(A) Schematic description of hPGCLC differentiation.(B) Representative flow-cytometry plots of day-4 aggregates in Ctrl UCLA1, T28KO(U1-9), T28KO(U1-11), Ctrl UCLA6, and T28KO(U6). The hPGCLC population is circled.(C) Average percentage of hPGCLCs at day 4 of aggregate differentiation in paired experiments of T28KO(U1-9) (n = 6 independent experiments) with Ctrl UCLA1 (n = 6 independent experiments), T28KO(U1-11) (n = 3 independent experiments) with Ctrl UCLA1 (n = 3 independent experiments), and T28KO(U6) (n = 3 independent experiments) with Ctrl UCLA6 (n = 3 independent experiments), ^∗∗^p \< 0.01, ^∗^p \< 0.05. Error bars represent SD.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Given that T28KO hESCs are germline incompetent, we hypothesized that there might be also somatic lineage bias, particularly given the pigmented teratomas. To address this, we performed spontaneous embryoid body (EB) differentiation and real-time PCR to examine ectoderm, mesoderm, and endoderm induction at days 2 and 5 of EB differentiation ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). We discovered some gene-specific differences between T28KO and Ctrl EBs, but collectively ectoderm (*SOX1*, *PAX6*, and *ZIC1*), endoderm (*SOX17*, *GATA6*, and *FOXA1*), and mesoderm (*MIXL1* and *TBX3*) genes were induced into T28KO EBs ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). One transcription factor, *HAND1*, was consistently lower in T28KO EBs at days 2 and 5 of EB differentiation experiments relative to Ctrls, suggesting that mesoderm cell lineage differentiation requiring *HAND1* (for example, the differentiation of cardiomyocytes) could be compromised. To address this, we performed directed differentiation into cardiomyocytes (CMs), and showed that the percentage of CMs was similar between Ctrl and T28KO at day 14 of differentiation ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). However, when normalized to the total number of undifferentiating hESCs used to initiate CM differentiation, the ratio of CMs generated per input of hESCs was significantly lower in T28KOs ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Taken together, a null mutation in TRIM28 had almost no effect on the basic properties of hESC self-renewal, and instead affects germline competency and the ability to maintain certain cell types derived from mesoderm, most notably CMs.

TRIM28 Is Required to Repress HERVHs, SVAs, and ZNFs in Primed hESCs {#sec2.3}
--------------------------------------------------------------------

Previous studies found that TRIM28 is bound to the chromatin of primed hESCs, and is specifically enriched at HERVs, LTRs, and SVA (SINE-R, VNTR, and Alu) TE subfamilies ([@bib31] and [Figure S3](#mmc1){ref-type="supplementary-material"}A). To examine how a null mutation in TRIM28 affects TE expression, we performed RNA sequencing (RNA-seq) and discovered that T28KO hESCs had an abundance (10,949) of differentially expressed TEs (DETEs) with a smaller number (670) of differentially expressed genes (DEGs) relative to Ctrl cells ([Figure 3](#fig3){ref-type="fig"}A; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). One of the DEGs was *TRIM28* ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Enrichment analysis of the DETEs revealed that this group was highly enriched in HERV, LTR, and SVAs as anticipated from chromatin immunoprecipitation sequencing (ChIP-seq) of TRIM28 in wild-type primed hESCs ([Figure 3](#fig3){ref-type="fig"}B).Figure 3TRIM28 Is Required to Repress HERVH and SVA Family Members in Primed hESCs(A) RNA-seq was used to detect DEG (n = 670) and DETE (n = 10,949) between Ctrl and T28KO(U1-9) primed hESCs.(B) Enrichment analysis of the DETE between Ctrl and T28KO(U1-9) primed hESCs in TE subfamilies. Fold enrichment is represented as log~2~(T28KO/Ctrl).(C--E) Box plots of TRIM28-enriched HERVH, HERVK, and SVA expression in Ctrl and T28KO(U1-9) primed hESC. "TRIM28 enriched" denotes any expressed HERVH/HERVK/SVA that were also defined as being bound by TRIM28 in wild-type primed hESC using the ChIP-seq dataset of [@bib31]. RPKM, reads per kilobase of transcript per million mapped reads.(F--K) Meta-plots showing the correlations between TRIM28 binding and chromatin accessibility at HERVH, HERVK, and SVA family members in Ctrl and T28KO(U1-9) primed hESCs. The four points on the x axis show, from left to right, 5 kbp upstream of TE, 5′ end of TE, 3′ end of TE, and 5 kbp downstream of TE.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Given the dynamic expression of HERVH and HERVK in human pre-implantation embryos and the re-expression of SVA when primed hESCs are switched to the naive state, we focused specifically on these subfamilies. Using the ChIP-seq dataset of [@bib31], we identified expressed HERVH, HERVK, and SVA TEs that were previously reported as being bound by TRIM28 in primed hESCs ([@bib31]). Of the 1,400 expressed HERVH sequences in our RNA-seq dataset (where expression was \>10 reads in at least one library) only 81 were bound by TRIM28, and on average these TEs were derepressed in T28KO hESCs relative to Ctrls ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). In contrast the 169 TRIM28-bound HERVKs were unchanged ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). Similar to HERVH subfamily members, the 293 TRIM28-bound SVAs were also significantly upregulated in T28KOs relative to Ctrls ([Figure 3](#fig3){ref-type="fig"}E). Therefore, TRIM28 had subfamily-specific effects on TE expression in primed hESCs, most notably repressing SVAs and HERVH TEs, with limited effects on HERVK RNA expression.

To determine how a TRIM28 deletion affects chromatin accessibility, we performed an assay for transposase-accessible chromatin sequencing (ATAC-seq) and showed that chromatin accessibility was also dynamically changed in the TE subfamily members bound by TRIM28 ([Figures 3](#fig3){ref-type="fig"}F--3K). Specifically, the 5′ end of HERVH exhibited increased accessibility in T28KO hESCs relative to Ctrl cells, and these new regions of accessibility occurred on average 2 kb upstream of the TRIM28 binding site ([Figure 3](#fig3){ref-type="fig"}F). The TRIM28 bound HERVK subfamilies exhibited increased accessibility exclusively at the 3′ but not the 5′ end of the TE ([Figure 3](#fig3){ref-type="fig"}H). ChIP-seq of TRIM28 in wild-type cells shows that TRIM28 is bound to both ends of the element ([Figure 3](#fig3){ref-type="fig"}I), and this might explain the lack of HERVK expression defects in T28KO hESCs with only one of the two ends becoming more accessible. TRIM28 bound SVA elements exhibit a mild increase in accessibility across the element body, consistent with TRIM28 binding across the element body in wild-type hESCs ([Figures 3](#fig3){ref-type="fig"}J and 3K). Taken together TRIM28-bound TEs show differences in accessibility upon deletion of TRIM28.

Given that TRIM28 is mostly enriched at TEs, yet we discovered 670 DEGs ([Table S1](#mmc2){ref-type="supplementary-material"}), we evaluated the correlation between DETEs and their nearest neighbor DEGs given that LTRs can function as promoters and enhancers ([@bib22]). Consistent with previous studies, our data indicate that at short ranges (within 5 kb), neighboring DEGs are highly correlated with differentially expressed LTRs (r = 0.71) or differentially expressed HERVs (r = 0.58) ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). At increasing distances this correlation diminishes (10 kb, r = 0.35 and 20 kb, r = 0.27 for LTRs). Therefore, similar to reports in the mouse, DEGs in the T28KO hESCs may be explained by the creation of new short-range promoters/enhancers at LTRs and HERVs of neighboring genes.

To determine whether there were any functional groups significantly enriched in the DEGs, we performed gene ontology analysis. To our surprise, we discovered that the DEGs were highly enriched in genes that encoded for Krüppel-associated box domain-containing zinc-finger proteins (KRAB-ZNFs) ([Figure S3](#mmc1){ref-type="supplementary-material"}I). There are 423 KRAB-ZNF genes located in 25 major clusters scattered around the human genome ([@bib11]). A subset of ZNF genes in a human erythroleukemic cell line was previously reported as being co-occupied by TRIM28, SETDB1, ATRX, and ZNF274 ([@bib33]). ZNF274 is expressed in undifferentiated hESCs but is not differentially expressed in T28KO hESCs, so our results cannot be explained by the repression of ZNF274.

To determine whether TRIM28 is enriched in the 3′ exons of the differentially expressed ZNFs, we first examined TRIM28 binding at the 728 ZNF genes identified by [@bib33] in somatic cells ([Figure S3](#mmc1){ref-type="supplementary-material"}J). Our data show a modest yet significant enrichment (p = 0.002) of TRIM28 at the 50 differentially expressed ZNFs in common with this dataset, which was mostly in the 3′ exons, as well as across the gene body ([Figure S3](#mmc1){ref-type="supplementary-material"}K); the control gene set are ZNFs that show no differences in gene expression between Ctrl and T28KO hESCs (log~2~ fold change \< 0.1). Therefore, we speculate that TRIM28 directly regulates a subset of ZNFs in primed pluripotent stem cells, and loss of TRIM28 is associated with their increased expression. Taken together, our data show that TRIM28 has subfamily-specific effects on TE expression in primed hESCs, most notably at HERVHs, LTRs, and SVAs. We also discovered that the genes regulated by TRIM28 include the ZNFs, which encode the sequence-specific binding partner KRAB-ZNF transcriptional regulators.

TRIM28 Regulates DNA Methylation and Chromatin States at LTRs, HERVKs, and LINEs in Primed hESCs {#sec2.4}
------------------------------------------------------------------------------------------------

Previous studies have identified a complex relationship between DNA methylation and TRIM28 in the mouse embryo ([@bib21], [@bib27], [@bib37]). Here, we examined how a null mutation in TRIM28 affects DNA methylation in primed hESCs. To achieve this, we performed whole-genome bisulfite sequencing (WGBS) of T28KO and Ctrl hESCs, and showed that global DNA methylation levels at CpGs sites remain high at \>80% ([Figure 4](#fig4){ref-type="fig"}A). To examine DNA methylation levels at regions specifically bound by TRIM28, we first identified all the TRIM28 bound regions that show increased accessibility in the T28KO hESCs ([Figure 4](#fig4){ref-type="fig"}B). Critically we discovered that only a small fraction of TRIM28 bound regions (477/7,885; 6%) exhibit a significant increase in chromatin accessibility (fold change ≥ 8, p \< 0.05) relative to Ctrl cells. Intriguingly, even though the 477 TRIM28 bound regions had increased accessibility, we discovered a more significant effect on the regions not bound by TRIM28. Specifically, we show that 2,224 new ATAC-seq peaks are gained in the T28KO hESCs relative to Ctrl ([Figure 4](#fig4){ref-type="fig"}B). In the current analysis, we focused on the 477 regions that were bound by TRIM28, and gained accessibility in the T28KO hESCs. Using the WGBS dataset, we show that the average DNA methylation levels of the 477 differentially accessible regions were significantly lower in T28KO hESCs compared with Ctrls ([Figure 4](#fig4){ref-type="fig"}C). Using enrichment analysis, we discovered that these 477 regions were enriched in HERVs, LTRs, and LINE elements ([Figure S4](#mmc1){ref-type="supplementary-material"}A and [Table S3](#mmc4){ref-type="supplementary-material"}). Box-plot analysis shows that average DNA methylation levels were dramatically reduced in HERVs, LTRs, and LINEs in T28KO compared with Ctrl hESCs ([Figures 4](#fig4){ref-type="fig"}D--4F). Further analysis of the hypomethylated HERVs (which are mainly composed of HERVKs) showed that their expression levels are unaffected between Ctrl and T28KO primed hESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B).Figure 4TRIM28 Regulates Local DNA Methylation Levels at LTRs, HERVKs, and LINEs in Primed hESCs(A) Quantification of CpG methylation using whole-genome bisulfite sequencing (WGBS) in 528,773 common CpGs for both Ctrl and T28KO(U1-9) primed hESCs (n = 2 independent replicates).(B) Venn diagram showing the overlap between TRIM28 binding sites in control cells using the dataset of [@bib31] and the emergence of new ATAC-seq peaks in T28KO(U1-9) hESCs.(C) Percent CpG methylation levels at the 477 overlapping regions in Ctrl and T28KO(U1-9) hESCs from (B).(D--F) Percent CpG methylation levels of HERV, LTR, and LINE from the 477 overlapping regions in Ctrl and T28KO(U1-9) hESC. Asterisk indicates that HERVs are mainly composed of HERVK.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

In addition to the 2,224 new ATAC-seq peaks in T28KO hESCs, we also discovered a large number of peaks (1,849) ([Table S3](#mmc4){ref-type="supplementary-material"}) that changed from accessible in Ctrls to inaccessible in the T28KO hESCs. None of these peaks overlapped with TRIM28 binding by ChIP-seq ([@bib31]). Loss of accessibility was particularly enriched in promoters, exons, 5′ UTRs, and coding regions ([Figure S4](#mmc1){ref-type="supplementary-material"}C). To determine how decreased accessibility in gene promoters corresponded to changes in DNA methylation, we calculated the average DNA methylation in the accessible promoters in Ctrl hESCs and the corresponding DNA methylation levels of these same inaccessible promoters in T28KO hESCs (n = 121 promoters). We discovered that in Ctrl cells these promoters began with low levels of DNA methylation, whereas in T28KO hESCs the promoters switch from low to high levels of DNA methylation ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Similarly, promoters that switch from inaccessible to accessible in T28KO hESCs switch from high to low levels of DNA methylation ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E), indicating that the chromatin accessibility in promoters is clearly inversely correlated with DNA methylation.

TRIM28 Is Required to Maintain DNA Methylation at Paternal but Not Maternal ICRs in Primed hESCs {#sec2.5}
------------------------------------------------------------------------------------------------

Given previous reports that TRIM28 is required to maintain DNA methylation at IAPs in mouse embryos and also at ICRs ([@bib1], [@bib18], [@bib20]), we next evaluated the role of TRIM28 at ICRs in primed hESCs. Notably, TRIM28 is not enriched at any of the maternal ICRs in primed hESCs (n = 29) and instead is only enriched at the two paternal ICRs called *IG-DMR* ([Figure 5](#fig5){ref-type="fig"}A) and the *H19* ICR ([Figure 5](#fig5){ref-type="fig"}B). This result is different from that in the mouse where TRIM28 is enriched at both maternal and paternal ICRs in mouse embryos ([@bib1], [@bib18]).Figure 5TRIM28 Is Required to Maintain DNA Methylation at Paternal but Not Maternal ICRs in Primed hESCs(A and B) TRIM28 binding at the IG-DMR and the H19-ICR relative to the average TRIM28 binding at 29 maternal ICRs as a control. ICR is underlined.(C) Percent CpG methylation levels at maternal imprinted ICRs in Ctrl and T28KO(U1-9) primed hESCs (n = 29 maternal ICRs), ns, not significant. Error bars represent SD.(D) Browser view of ATAC-seq (blue), WGBS (green), and TRIM28 ChIP-seq (yellow) at the IG-DMR ICR, the MEG3 promoter, and the H19 ICR.(E and F) Relative expression using real-time RT-PCR of *MEG3* and *H19* in T28KO(U1-9) primed hESCs relative to Ctrl. ^∗∗∗∗^p \< 0.0001. Error bars represent SD.(G--J) ChIP-qPCR of TRIM28 and H3K9me3 at the MEG3 promoter and H19-ICR, in Ctrl and T28KO(U1-9) hESCs.(K) Sanger sequencing of SNPs in primed Ctrl and T28KO(U1-9) hESCs and naive hESCs as a control for biallelic expression. Arrows indicate two independent H19 SNPs.

Next we evaluated DNA methylation levels at the maternal and paternal ICRs in Ctrl and T28KO hESCs. We discovered variable imprinting methylation levels at individual ICRs in hESCs as previously reported ([@bib12], [@bib19], [@bib24]). However, on average, DNA methylation levels at maternal ICRs in Ctrl and T28KO hESCs were around 50% ([Figure 5](#fig5){ref-type="fig"}C). At the *MEG3* paternally methylated imprinted locus, we discovered that the *IG-DMR* and the *MEG3* promoter were demethylated in the T28KOs, relative to Ctrls, and this was associated with increased chromatin accessibility ([Figure 5](#fig5){ref-type="fig"}D). A similar change in chromatin was also observed at the *H19* ICR ([Figure 5](#fig5){ref-type="fig"}D). Consistent with demethylation and the emergence of accessible chromatin, the expression levels of *MEG3* and *H19* RNA transcripts were both increased in T28KO cells relative to Ctrls ([Figures 5](#fig5){ref-type="fig"}E and 5F). Taken together, our results suggest that TRIM28 is required to continually target the paternal ICRs for DNA methylation. Critically, maternal ICRs in hESCs do not require TRIM28 to remain methylated.

To determine whether the effects at the *MEG3* promoter were direct, we evaluated TRIM28 binding by chromatin immunoprecipitation followed by PCR (ChIP-qPCR) ([Figure 5](#fig5){ref-type="fig"}G). Our results show that TRIM28 is bound at the *MEG3* promoter in Ctrl cells, with no binding in the T28KOs. Therefore TRIM28 is most likely acting on both the *IG-DMR* and the *MEG3* promoter. Similarly, we also confirmed that TRIM28 is bound at the *H19* ICR in Ctrl hESCs ([Figure 5](#fig5){ref-type="fig"}H), and this binding is lost in the T28KOs. We also performed ChIP-qPCR for histone h3 lysine 9 trimethylation (H3K9me3), which is a known effector of TRIM28 binding on account of TRIM28\'s interaction with SETDB1 ([@bib27]). Our data show that H3K9me3 is also reduced at the *MEG3* promoter, as well as the *H19* ICR in T28KO cells ([Figures 5](#fig5){ref-type="fig"}I and 5J). To determine whether this loss of methylation affects allelic expression, we examined the SNP in the *H19* RNA transcribed in the UCLA1 hESC line ([@bib19]). Using these SNPs as a reference, we show that TRIM28 is required to prevent loss of imprinting and maintain monoallelic expression of *H19* in self-renewing hESCs ([Figure 5](#fig5){ref-type="fig"}K). Taken together, TRIM28 plays highly localized and precise roles in the paternally methylated ICRs where it acts to promote H3K9me3 and DNA methylation in the self-renewing primed state.

TRIM28 Represses a Broad Range of Transposable Elements in Naive hESCs {#sec2.6}
----------------------------------------------------------------------

Major transcriptional and epigenetic changes occur when primed hESCs are reverted to the naive state. Most notably, ICRs lose DNA methylation, LTR7-HERVH TEs are repressed, and SVA TEs are induced ([@bib19], [@bib31]). To evaluate the effects of TRIM28 upon reversion to the naive state, we reverted Ctrl and T28KO hESCs in the ground-state naive medium called 5iLAF ([@bib30]). Starting from passages 3--5 post reversion, both Ctrl and T28KO putative naive hESC exhibited typical small, round colonies ([Figure 6](#fig6){ref-type="fig"}A). We have successfully generated naive hESC lines from both T28KO(U1-9) and T28KO(U1-11) primed hESCs (data not shown). RNA-seq of stage-specific embryonic antigen 4 (SSEA4)-negative, TRA-1--85-positive naive hESCs ([@bib19]) from Ctrl and T28KO 5iLAF cultures revealed that primed-specific genes *OTX2*, *ZIC2*, *ZIC3*, and *ZIC5* were downregulated in naive T28KO and Ctrl hESCs, whereas the naive-specific genes *KLFs*, *DPPA3*, and *TFCP2L1* were significantly upregulated. The RNA-seq analysis did reveal that T28KO naive hESCs had lower average expression of *NANOG* (fold change = 1.82) and *DPPA3* (fold change = 1.80) compared with Ctrl hESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}A), although this did not reach statistical significance (defined as fold change ≥ 2, false discovery rate \< 0.05). No morphological differences in colonies were observed between Ctrl and T28KO naive hESCs under phase-contrast microscopy, suggesting that a null mutation in TRIM28 is also compatible with naive stem cell self-renewal in human. However, we did discover that T28KO naive hESCs grow more slowly than Ctrl naive hESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}B). We used array comparative genomic hybridization (aCGH) to determine copy number variants (CNVs) in these two cell lines, which showed that the naive Ctrl hESCs have normal CNVs while the T28KO naive hESCs have two deletions at chromosome 20 and chromosome 22 that do not overlap with normal CNVs ([Figure S5](#mmc1){ref-type="supplementary-material"}C).Figure 6Naive hESCs Are Dependent upon TRIM28 for TE Repression but Not Self-Renewal(A) Morphology of 5iLAF reverted Ctrl and T28KO(U1-9) naive hESCs. Scale bars, 100 μm.(B) RNA-seq of Ctrl and T28KO(U1-9) naive hESCs showing DEGs (n = 1,638) and DETEs (n = 12,350).(C) Box plots showing percentage of CpG methylation levels in Ctrl and T28KO(U1-9) hESCs in the primed and naive states (n = 2 independent samples of each genotype in each pluripotent state).(D--G) Scatterplots showing selected DETEs between Ctrl and T28KO(U1-9) naive hESCs. Red dots, significantly upregulated; blue dots, significantly downregulated; black dots, unchanged. Expression values are represented as RPKM.(H--K) Percent CpG methylation of TEs shown in (D) to (G). Dotted lines, CpG methylation in T28KO; solid lines, the same regions in Ctrl.(L) Representative tracks of RNA-seq, WGBS, and ChIP-seq at a representative HERVH, HERVK, and SVA.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Although TE expression is altered in primed hESCs with a null mutation in *TRIM28*, ChIP-seq data of TRIM28 in wild-type 5iLAF cultures shows that significantly more TEs are bound by TRIM28 under 5iLAF naive conditions ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Consistent with this, reverting *TRIM28* null hESCs to the naive state results in 12,350 DETEs ([Figure 6](#fig6){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). Enrichment analysis of the DETE identified HERV and LTR families, as well as SVAs ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Similar to the effects of TRIM28 on primed hESCs, we also discovered 1,638 DEGs ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

We next evaluated changes in DNA methylation in naive T28KO cells relative to Ctrl cells ([Figure 6](#fig6){ref-type="fig"}C). As expected, reversion to the naive state also resulted in a global loss of DNA methylation from an average of 74.5% in primed cells to an average of 42.4% in the naive state. In naive T28KO hESCs we discovered that DNA methylation was also globally reduced ([Figure 6](#fig6){ref-type="fig"}C). However, the average levels of global DNA methylation were slightly higher in the naive T28KOs (50.15% versus 42.4%). This translated to significantly more hypermethylated DMRs in the T28KO hESCs (2,552) and only a small number of hypomethylated regions (578). Notably, the hypomethylated DMRs were particularly enriched in SVAs and HERVs ([Figure S5](#mmc1){ref-type="supplementary-material"}G and [Table S3](#mmc4){ref-type="supplementary-material"}).

To determine the relationship between TRIM28 and DNA methylation in the hypomethylated naive state, we combined the ChIP-seq dataset of TRIM28 in naive hESCs ([@bib31]), with the RNA-seq and WGBS data of T28KO and Ctrl naive hESCs generated in this study. This comparison identified subfamilies of TRIM28 bound HERVHs, HERVKs, and SVAs that were significantly affected at both the RNA and DNA methylation level ([Figures 6](#fig6){ref-type="fig"}D--6K and [Table S4](#mmc5){ref-type="supplementary-material"}). Notably, HERVH family members were both up- and downregulated in T28KO hESCs ([Figure 6](#fig6){ref-type="fig"}D), with upregulated HERVHs exhibiting an extra peak of TRIM28 binding in wild-type cells ([Figures S5](#mmc1){ref-type="supplementary-material"}H and [6](#fig6){ref-type="fig"}L). Of the 60 HERVH elements that were identified as upregulated in primed hESCs, 15 of 60 remained upregulated following reversion to the naive state. However, 60 HERVH family members were newly upregulated in naive T28KO hESCs relative to Ctrl, including the primed-specific LTR7-HERVHs ([Table S4](#mmc5){ref-type="supplementary-material"}). Similarly LTRs were also highly enriched in TRIM28 binding in the naive state, and consistent with this, T28KO naive cells had increased RNA expression from LTRs ([Figure 6](#fig6){ref-type="fig"}E). Interestingly, the differentially upregulated LTRs did not show obvious loss of DNA methylation below the genome average, indicating that LTRs are regulated primarily by TRIM28 ([Figure 6](#fig6){ref-type="fig"}I). In the primed state, TRIM28 null mutations had no significant effect on HERVK RNA expression ([Figure 3](#fig3){ref-type="fig"}D). In contrast, HERVK elements were now derepressed in T28KO naive hESCs relative to Ctrls ([Figure 6](#fig6){ref-type="fig"}F), and this was also accompanied by changes in DNA methylation ([Figures 6](#fig6){ref-type="fig"}J and 6L). Therefore, expression of HERVK subfamily members was particularly sensitive to loss of TRIM28 in the naive state compared with the primed state.

Although naive human pluripotency under wild-type conditions is associated with expression of SVAs at the expense of LTR7-HERVH, a TRIM28 null mutation in naive hESCs leads to further upregulation of SVA family members, and this is associated with loss of methylation particularly at their 5′ regions ([Figures 6](#fig6){ref-type="fig"}G and 6K). Taken together, TRIM28 has an important role in regulating the expression and DNA methylation levels of TEs in the naive state, particularly the repression of LTR7-HERVHs, HERVKs and SVAs.

Discussion {#sec3}
==========

In the current study, we show that self-renewal of hESCs in the naive and primed states of human pluripotency are compatible with significant changes in TE expression, accompanied by changes in chromatin accessibility and DNA methylation, particularly at HERVs and LTRs. This result is unlike the biological response in mouse pluripotent cells, where a *Trim28* null mutation in mouse cells is incompatible with mouse ESC self-renewal and mouse embryo development ([@bib2], [@bib23]). One explanation for these species-specific differences in response to loss of TRIM28 is that the primed state of hESC pluripotency is more similar to mouse epiblast stem cells (EpiSCs) than mouse ESCs ([@bib29]). Generating a TRIM28 null mutation in mouse EpiSCs in future studies will address this issue.

It is also possible that the modest biological effect on human pluripotent stem cell self-renewal in the absence of human TRIM28 relative to the mouse is a consequence of the unique repertoire of provirus that infected and expanded in rodent genomes relative to humans, where it is possible that the rodent TEs today are more mutagenic and/or deleterious when derepressed in the absence of TRIM28 ([@bib5], [@bib36]). In the human genome, most TEs are ancient non-functional relics of past proviral infections that have lost transposition competency. Furthermore, our data also suggest that the continued targeting of TRIM28 to TE-associated chromatin is not the primary defense for most TE repression in human pluripotent stem cells, because a large fraction of the TRIM28-bound TEs remained unperturbed in both the primed and the naive state when TRIM28 was deleted.

Given that hESCs with a TRIM28 null mutation are biased against hPGCLC differentiation, we speculate that this occurs as an unintended consequence of dynamically changing accessibility of local chromatin in human primed pluripotent hESCs. The differentiation of hPGCLCs from pluripotent stem cells requires a narrow window in development where the same signaling pathways used to generate primitive streak (notably, ACTIVIN, WNTs, and bone morphogenetic protein 4 \[BMP4\]) are also required to specify hPGCLCs. It was previously reported that changes to the concentrations of growth factors that promote hPGCLC differentiation also significantly affect germline competency ([@bib25]). We propose that for lineages where the window for competency is very narrow (such as the allocation of hPGCLCs from hESCs), small changes in the response to somatic cell signaling cues bias against germline fate.

We also discovered that unlike mouse ESCs where mouse TRIM28 regulates DNA methylation at almost all ICRs ([@bib1]), human TRIM28 is only responsible for regulating DNA methylation at the paternally methylated ICRs in human pluripotent stem cells. Previous studies have shown that ICR methylation in primed hESCs is not regulated by the *de novo* DNA methyltransferases DNMT3A or DNMT3B ([@bib15]). These results may suggest that DNMT1 re-targets discrete paternal ICRs and promoters together with TRIM28 outside of replication-coupled DNA methylation maintenance, given that the paternally methylated ICRs were so specifically and discretely targeted. Alternatively, it is conceivable that a previously undiscovered DNMT may have evolved to interact with TRIM28 to target DNA methylation specifically to paternal ICRs.

TRIM28 itself has no sequence specificity. Instead, TRIM28 binds to ZNFs, which target TRIM28 to discrete sites in a sequence-dependent manner. The ZNF responsible for targeting TRIM28 to ICRs in the mouse genome (ZFP57) is also responsible for some ICR methylation in the human genome. Specifically, a homozygous deletion of ZFP57 in human is compatible with life, germ cell development, and fertility, with homozygous children exhibiting variable ICR hypomethylation mostly at maternal ICRs ([@bib17]). In light of our findings it is possible that ZFP57 targets maternal ICRs for DNA methylation in a TRIM28-independent mechanism, or alternatively that TRIM28 targets paternal ICRs by a ZFP57-independent mechanism. Future studies could be designed to address these hypotheses.

Previous reports have shown that in the majority of reversions in 5iLAF, hESCs exhibit karyotypic instability ([@bib19], [@bib30]). In the current study, the Ctrl naive hESCs had a normal karyotype based on CNV analysis. However, we discovered that the T28KO naive hESCs cultured under identical conditions developed abnormal CNVs. It has previously been reported that SVA expression causes genome instability and even diseases ([@bib14]). Therefore, we hypothesize that one of the possible mechanisms associated with increased genome instability may be due to increased SVA expression in the naive state.

Taken together, TRIM28 has broadly conserved roles in human and mouse pluripotent stem cells where it functions to regulate TE expression, and this is associated with changes in the landscape of chromatin accessibility and DNA methylation. However, our data also highlight species-specific differences in the naive state of pluripotency including the finding that human naive pluripotent stem cells tolerate significant changes in TE expression downstream of a TRIM28 mutation. We also show, surprisingly, that TRIM28 has a preference for targeting paternal ICRs in the primed self-renewing state rather than ICRs more broadly. We were also able to uncover a role for TRIM28 in germline competency, and future studies will involve identifying the ZNFs responsible for these different phenotypes.

Experimental Procedures {#sec4}
=======================

Primed and Naive hESC Culture {#sec4.1}
-----------------------------

Primed and naive hESCs were cultured as previously described ([@bib19]). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details. All hESC studies were approved by the UCLA Embryonic Stem Cell Research Oversight (ESCRO) Committee.

Generation of TRIM28 Knockout Primed hESC Line {#sec4.2}
----------------------------------------------

Taking advantage of the CRISPR/Cas9 targeting technology in mammalian cells ([@bib3]), we designed paired gRNAs that target exon 4 and exon 11 of the human *TRIM28* genome, respectively, using the [crispr.mit.edu](http://crispr.mit.edu){#intref0010} web site, and ligated the gRNAs with px459 vector to obtain the final constructs. Two micrograms of each targeting vector (4 μg in total) were electroporated into 800K human ESCs, and we used the P3 Primary Cell 4D-Nucleofector X Kit to perform the nucleofection following manufacturer\'s instructions. The cells were transferred to one well of a 24-well plate with feeders post nucleofection, and on the next day, 0.35 μg/mL puromycin was added to the medium as a primary screen of successfully electroporated cells for 24 hr. The medium was then changed back to regular hESC medium + ROCKi for another 3 days until cells were densely grown. Cells were then split by Accutase and transferred as 2K and 10K per dish onto 10-cm dishes with feeders. After 10--14 days when the colonies were big enough, single colonies were picked manually, and the genomic DNA of each line was extracted and genotyped. The homozygous *TRIM28* knockout lines were then expanded for further analysis. The gRNA sequences are: 5′-ACG TTC ACC ATC CCG AGA CT-3′ for exon 4 and 5′-GGT GAG CGG CCT TAT GCG CA-3′ for exon 11.

hPGCLC Differentiation {#sec4.3}
----------------------

Primed hESCs were differentiated into hPGCLC as described in [@bib25] with some modifications. Day-7 hESCs were dissociated into single cells with 0.05% trypsin-EDTA (Gibco) and plated onto a human plasma fibronectin (Invitrogen)-coated 12-well-plate at 200,000 cells/well cell density in 2 mL/well of incipient mesoderm-like cells (iMeLCs) medium, which is composed of 15% knockout serum replacement (KSR), 1× non-essential amino acids (NEAA), 0.1 mM 2-mercaptoethanol, 1× penicillin-streptomycin-glutamine (Gibco), 1 mM sodium pyruvate (Gibco), 50 ng/mL Activin A (Peprotech), 3 μM CHIR99021 (Stemgent), 10 μM ROCKi (Y27632, Stemgent), and 50 ng/mL primocin in Glasgow\'s minimal essential medium (GMEM) (Gibco). Twenty-four hours later, iMeLCs were dissociated into single cells by 0.05% trypsin-EDTA, followed by plating onto ultra-low cell attachment U-bottom 96-well plates (Corning) at a density of 3,000 cells/well in 200 μL/well of hPGCLC medium, which is composed of 15% KSR, 1× NEAA, 0.1 mM 2-mercaptoethanol, 1× penicillin-streptomycin-glutamine (Gibco), 1 mM sodium pyruvate (Gibco), 10 ng/mL human leukemia inhibitory factor (Millipore), 200 ng/mL human BMP4 (R&D systems), 50 ng/mL human epidermal growth factor (R&D Systems), 10 μM of ROCKi (Y27632, Stemgent), and 50 ng/mL primocin in GMEM (Gibco). Day-4 hPGCLC aggregates were used for further analysis.

hPGCLC Flow-Cytometry Analysis {#sec4.4}
------------------------------

Day-4 hPGCLC aggregates were dissociated with 0.05% trypsin-EDTA for 10 min at 37°C. The dissociated cells were stained with antibodies, which were INTEGRINα6 conjugated with BV421 (BioLegend) and EpCAM conjugated with 488 (BioLegend) for at least 1 hr on ice. Cells were then washed with FACS buffer (1% BSA in PBS) once and resuspended in FACS buffer with 7-aminoactinomycin D (BD Pharmingen). Finally, cells were passed through a 40-μm cell strainer (Fisher Scientific) and used for flow-cytometric analysis.

RNA-Seq {#sec4.5}
-------

Cells were centrifuged and cell pellets lysed in 350 μL of RLT buffer, and total RNA was extracted using an RNeasy micro kit (Qiagen) or RNeasy mini kit (Qiagen). cDNA was amplified using Ovation RNA-Seq System V2 (Nugen) according to the manufacturer\'s instructions. Amplified cDNA was then sheared to ∼200 bp length by a Covaris S220 Focused ultrasonicator. RNA-seq libraries were constructed by using Ovation Rapid Library Systems (Nugen, 0319-32 for index 1--8 and 0320-32 for index 9--16) and quantified by a KAPA library quantification kit (Illumina). Libraries were subjected to single-end 50-bp sequencing on a HiSeq 2500/4000 sequencer with 4--6 indexed libraries per lane.

ATAC-Seq {#sec4.6}
--------

Cells were lysed directly in lysis buffer (500 μL 1 M Tris \[pH 7.4\], 100 μL 5 M NaCl, 150 μL 1 M MgCl~2~, 500 μL 10% NP-40 in 50 mL water). After centrifugation, the cell pellet was resuspended in transposase buffer, which contained the Tn5 transposase enzyme and tagmentation buffer (Nextera DNA library prep kit: Illumina, catalog no. 15028212), and incubated at 37°C for 30 min. After purification by a MinElute PCR Purification Kit 250 (Qiagen 28006), P1 barcode (25 μM) and appropriate P2 barcodes (25 μM) were added to the DNA and run for five cycles of PCR reaction (NEBNext High-Fidelity 2× PCR Master Mix; NEB, M0541S). Ten percent of the PCR product was taken out for real-time PCR analysis to determine the amplification cycles of the library, followed immediately by PCR amplification of the remaining library DNA. Libraries were subjected to paired-end 50-bp sequencing on a Hi Seq 4000 sequencer with 4--6 indexed libraries per lane.

Whole-Genome Bisulfite Sequencing {#sec4.7}
---------------------------------

DNA for bisulfite sequencing was extracted using the Quick gDNA Mini-Prep Kit (Zymo D3025) and quantified using the Qubit dsDNA High Sensitivity Kit (Life Technologies). Bisulfite sequencing libraries were prepared using the Ovation Ultralow Methyl-Seq Library System (Nugen, 0335 for DR Multiplex System 1--8, 0336 for DR Multiplex System 9--16). Libraries were subjected to single-end 100-bp sequencing on HiSeq 4000 sequencer with about 1 sample per lane to achieve coverage.
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